Strategies for the preclinical and clinical characterization of immunogenicity.
作者信息
Koren E, Mytych D, Koscec M, Ferbas J, Gupta S, Moxness M, Swanson S
机构信息
Department of Clinical Immunology, Amgen Inc, Thousand Oaks, California 91320, USA.
出版信息
Dev Biol (Basel). 2005;122:195-200.
PMID:16375262
Abstract
摘要
相似文献
1
Strategies for the preclinical and clinical characterization of immunogenicity.免疫原性临床前和临床特征分析策略。
Dev Biol (Basel). 2005;122:195-200.
2
Recent Advances in Assessing Immunogenicity of Therapeutic Proteins: Impact on Biotherapeutic Development.治疗性蛋白质免疫原性评估的最新进展：对生物治疗药物研发的影响
J Immunol Res. 2016;2016:8141269. doi: 10.1155/2016/8141269. Epub 2016 Aug 23.
3
Models for evaluation of relative immunogenic potential of protein particles in biopharmaceutical protein formulations.评估生物制药蛋白制剂中蛋白颗粒相对免疫原性的模型。
J Pharm Sci. 2012 Oct;101(10):3586-92. doi: 10.1002/jps.23248. Epub 2012 Jun 26.
4
Workshop on predictive science of the immunogenicity aspects of particles in biopharmaceutical products.生物制药制品中颗粒的免疫原性方面的预测性科学研讨会。
J Pharm Sci. 2012 Oct;101(10):3555-9. doi: 10.1002/jps.23243. Epub 2012 Jun 26.
5
Safety issues specific to clinical development of protein therapeutics.蛋白质治疗药物临床开发特有的安全性问题。
Clin Pharmacol Ther. 2008 Nov;84(5):624-7. doi: 10.1038/clpt.2008.158. Epub 2008 Aug 13.
6
The future of protein particle characterization and understanding its potential to diminish the immunogenicity of biopharmaceuticals: a shared perspective.蛋白质颗粒表征的未来及其降低生物制药免疫原性的潜力：共同视角。
J Pharm Sci. 2012 Oct;101(10):3580-5. doi: 10.1002/jps.23247. Epub 2012 Jun 26.
7
Is the tiered immunogenicity testing of biologics the adequate approach in preclinical development?
Bioanalysis. 2013 Apr;5(7):743-6. doi: 10.4155/bio.13.43.
8
Managing uncertainty: a perspective on risk pertaining to product quality attributes as they bear on immunogenicity of therapeutic proteins.管理不确定性：从风险角度看待与治疗性蛋白的免疫原性相关的产品质量属性。
J Pharm Sci. 2012 Oct;101(10):3560-7. doi: 10.1002/jps.23244. Epub 2012 Jun 26.
9
Pre-clinical considerations in the assessment of immunogenicity for protein therapeutics.蛋白质治疗药物免疫原性评估中的临床前考量
Curr Drug Saf. 2010 Oct;5(4):308-13. doi: 10.2174/157488610792246000.
10
Protein particles: what we know and what we do not know.蛋白质颗粒：已知与未知。
J Pharm Sci. 2012 Oct;101(10):3568-79. doi: 10.1002/jps.23242. Epub 2012 Jun 26.
Zotero 插件